Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis Journal Article

  

Authors:	Janjigian, Y. Y.; Werner, D.; Pauligk, C.; Steinmetz, K.; Kelsen, D. P.; Jager, E.; Altmannsberger, H. M.; Robinson, E.; Tafe, L. J.; Tang, L. H.; Shah, M. A.; Al-Batran, S. E.
Article Title:	Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis
Abstract:	Background: To determine whether human epidermal growth factor receptor 2 (HER2) status is an independent prognostic factor in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Patients and methods: Formalin-fixed paraffin-embedded tumor samples from 381 metastatic gastric/GEJ cancer patients enrolled at Krankenhaus Nordwest and Memorial Sloan-Kettering Cancer Centers on six first-line trials of chemotherapy without trastuzumab were examined for HER2 by immunohistochemistry (IHC) and in situ hybridization (ISH). IHC 3+ or ISH-positive tumors were considered HER2 positive. Results: Seventy-eight of 381 patients (20%) had HER2-positive disease. In the multivariate logistic model, there were significantly higher rates of HER2 positivity in patients with liver metastasis (liver metastasis 31%; no liver metastasis 11%; P = 0.025) and intestinal histology (intestinal 33%; diffuse/mixed 8%; P = 0.001). No significant differences in HER2 positivity were found between resections and biopsies or primaries and metastases. Patients with HER2-positive gastric cancer had longer median overall survival compared with HER2-negative gastric cancer patients (13.9 versus 11.4 months, P = 0.047), but multivariate analysis indicated that HER2 status was not an independent prognostic factor (hazard ratio 0.79; 0.44-1.14; P = 0.194). Conclusions: Approximately 20% of Western patients with metastatic gastric cancer are HER2 positive. Unlike breast cancer, HER2 positivity is not independently prognostic of patient outcome in metastatic gastric or GEJ. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Keywords:	gastric cancer; gastroesophageal cancer; esophagogastric cancer; human epidermal growth factor receptor 2 (her2)
Journal Title:	Annals of Oncology
Volume:	23
Issue:	10
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2012-10-01
Start Page:	2656
End Page:	2662
Language:	English
DOI:	10.1093/annonc/mds104
PROVIDER:	scopus
PUBMED:	22689179
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84867131579&partnerID=40&md5=d389796af53539b947622c8bb21a32f2
Notes:	--- - "Export Date: 2 November 2012" - "Art. No.: mds104" - "CODEN: ANONE" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/36200